Accueil・Liste d'Actions・ADMA Biologics Inc

ADMA Biologics Inc

Ouvert

SecteurSoins de santé

9.47 0.64

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.23

Max

9.52

Chiffres clés
By Trading Economics
Revenu	-7.5M 38M
Ventes	9.9M 124M
P/E Moyenne du Secteur	13.929 57.002
BPA	0.16
Marge bénéficiaire	30.405
Employés	640
EBITDA	-3.8M 57M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+80.66% upside

Dividendes
By Acuity
Prochains Résultats	4 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	158M 2.2B
Ouverture précédente	8.83
Clôture précédente	9.47

Sentiment de l'Actualité

By Acuity

100%

325 / 340 Classement par Healthcare

ADMA Biologics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12 août 2026, 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11 août 2026, 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7 août 2026, 19:46 UTC

Correlated Moves

News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6 août 2026, 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5 août 2026, 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4 août 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3 août 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31 juil. 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30 juil. 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29 juil. 2026, 18:17 UTC

News

Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28 juil. 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27 juil. 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24 juil. 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 juil. 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 juil. 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 juil. 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Comparaison

Variation de prix

ADMA Biologics Inc prévision

Objectif de Prix

By TipRanks

80.66% hausse

Prévisions sur 12 Mois

Moyen 17 USD 80.66%

Haut 21 USD

Bas 12 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

325 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.